<SEC-DOCUMENT>0001214659-23-005237.txt : 20230412
<SEC-HEADER>0001214659-23-005237.hdr.sgml : 20230412
<ACCEPTANCE-DATETIME>20230412090157
ACCESSION NUMBER:		0001214659-23-005237
CONFORMED SUBMISSION TYPE:	PX14A6G
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20230412
DATE AS OF CHANGE:		20230412
EFFECTIVENESS DATE:		20230412

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		PX14A6G
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		23814748

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Oxfam America, Inc.
		CENTRAL INDEX KEY:			0001764188
		IRS NUMBER:				237069110
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0319

	FILING VALUES:
		FORM TYPE:		PX14A6G

	BUSINESS ADDRESS:	
		STREET 1:		226 CAUSEWAY ST
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02114
		BUSINESS PHONE:		8007769326

	MAIL ADDRESS:	
		STREET 1:		226 CAUSEWAY ST
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02114
</SEC-HEADER>
<DOCUMENT>
<TYPE>PX14A6G
<SEQUENCE>1
<FILENAME>d412230px14a6g.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;<IMG SRC="oxfamlogo.jpg" ALT=""></P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Notice of Exempt Solicitation</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NAME OF REGISTRANT:&nbsp;</B>Johnson &amp; Johnson (JNJ)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>NAME OF PERSON RELYING ON EXEMPTION: </B>Oxfam America<B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>ADDRESS OF PERSON RELYING ON EXEMPTION:&nbsp;</B><FONT STYLE="font-size: 10pt">77
North Washington Street, Suite 5-1, Boston, MA 02114&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 0.75pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Written materials are submitted pursuant to
Rule 14a-6(g)(1) promulgated under the Securities Exchange Act of 1934. Submission is not required of this filer under the terms of the
Rule, but is made voluntarily in the interest of public disclosure and consideration of these important issues.</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge shareholders to vote <B>&ldquo;For&rdquo;</B>
Item 6 at JNJ&rsquo;s annual general meeting (AGM) on April 27, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>I. SUMMARY OF RESOLUTION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<DIV STYLE="padding: 1%; border: Black 1pt solid">



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RESOLVED that shareholders
of Johnson &amp; Johnson (&ldquo;JNJ&rdquo;) ask the Board of Directors to report to shareholders, at reasonable expense and omitting
confidential and proprietary information, on whether and how JNJ subsidiary Janssen&rsquo;s receipt of government financial support for
development and manufacture of vaccines and therapeutics for COVID-19 is being, or will be, taken into account when engaging in conduct
that affects access to such products, such as setting prices.</P>
</DIV>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Supporting Statement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">COVID-19 continues to cause deaths, long-term
health consequences, and economic disruption for millions of people. Vaccines and therapeutics are essential tools to reduce mortality
and vaccines can reduce the emergence of more transmissible and vaccine-resistant variants that can prolong the pandemic and further strain
the global economy.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Janssen
received more than $2 billion in US public funding for COVID-19-related vaccine research, development, manufacturing, and advanced purchase
agreements.<SUP>1</SUP> The
government additionally provided $152 million for Janssen and a partner to develop COVID-19 therapeutics.<SUP>2</SUP>
The vaccine has brought in more than $4.5 billion in revenues in two years and was among JNJ&rsquo;s top 10 pharmaceutical products by
revenue in 2022.<SUP>3</SUP></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>1</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.medicalcountermeasures.gov/app/barda/coronavirus/COVID19.aspx</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>2</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.reuters.com/article/health-coronavirus-usa-funding/factbox-u-s-pours-billions-into-development-of-coronavirus-vaccines-tests-idINL4N2D32T5</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>3</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://johnsonandjohnson.gcs-web.com/static-files/ca8c3ac2-15ab-4f8d-9693-f604d50be358</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JNJ
has been distributing its COVID-19 vaccine on a &ldquo;nonprofit&rdquo; basis, but that commitment is limited to &ldquo;emergency pandemic
use,&rdquo; without clarification on how the end of emergency pandemic use will be determined.</FONT><SUP>4</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">JNJ has not clarified what &ldquo;nonprofit&rdquo; means when
the government has funded a portion of the research and development costs, nor what prices the company will charge and which access measures
will be applied post-emergency pandemic if people continue to need vaccines and boosters. This Proposal asks JNJ to explain how the contribution
from public entities affects its actions, including pricing determinations, that impact access to COVID-19 products. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">JNJ&rsquo;s current approach, which provides no
transparency for how it factors in public funding in its access decisions, could lead to reputational risks for the company and risks
increased government regulation and oversight. Shareholders should be given the opportunity to understand how JNJ is accounting for public
funding in its current and future pricing and access strategies for its COVID-19 products. We urge shareholders to vote FOR this proposal.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><U>II. ARGUMENTS IN FAVOR OF A FOR VOTE</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>1.</B></TD><TD STYLE="text-align: justify"><B>JNJ&rsquo;s approach to access to its COVID-19 vaccine has already and could continue to generate reputational
risks for JNJ and its investors. </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">JNJ faces reputational risk with respect to how
the company has managed pricing and access, particularly given the scale of public funding and the public attention to COVID-19 vaccines.
JNJ has already faced significant criticism during this pandemic when <I>The New York Times </I>reported that the company had transferred
COVID-19 vaccine doses bottled and packed at Aspen Pharmaceutical in South Africa to the European Union, even as there was a significant
shortage of vaccine doses in South Africa (and on the African continent), inadequate vaccination of the population, and a worsening pandemic.<SUP>5</SUP>
According to the news report, at least 32 million doses of vaccine were exported from South Africa to the European Union. The decision
to export these doses was met with outrage from African governments, the World Health Organization (WHO), and public health organizations
and activists around the world who &ldquo;rebuked&rdquo; and &ldquo;slammed&rdquo; the company for the move, as media coverage notes.<SUP>6</SUP>
JNJ has also attracted negative media attention with <I>The New York Times</I> reporting JNJ is &ldquo;locked in a bitter dispute&rdquo;
with Gavi, the Global Vaccine Alliance <FONT STYLE="background-color: white">&ldquo;over payment for shots that Gavi told the company
months ago it would not need, but which the company produced anyway&rdquo; after failing to supply doses in a timely way</FONT>.<SUP>7</SUP>
Other reports detail similar experiences for South Africa, further noting that of the doses that were delivered, some arrived thawed with
shorter-than-expected shelf life.<SUP>8</SUP> These concerns
create a significant reputational risk for both JNJ and its investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>4</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.jnj.com/johnson-johnson-covid-19-vaccine-authorized-by-u-s-fda-for-emergency-usefirst-single-shot-vaccine-in-fight-against-global-pandemic</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>5</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.nytimes.com/2021/08/16/business/johnson-johnson-vaccine-africa-exported-europe.html</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>6</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.usnews.com/news/world/articles/2021-08-19/eu-says-import-of-j-j-vaccines-from-south-africa-is-temporary</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;
https://apnews.com/article/europe-africa-business-health-coronavirus-pandemic-9996bb1487e1197580070eaa44f3f420. The company has also been
harshly criticized for taking &ldquo;the only plant making <FONT STYLE="background-color: white">usable batches of the vaccine&rdquo;
offline for up to six months after delivering only 40% of projected doses last year. &ldquo;We really needed their doses in 2021, and
we were counting on them,&rsquo; Dr. Berkley [of Gavi, the Vaccine Alliance, on behalf of COVAX], said. &lsquo;They didn&rsquo;t deliver.
So we had to find other doses to meet the countries&rsquo; needs.&rsquo;&rdquo; </FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.nytimes.com/2022/02/08/business/johnson-johnson-covid-vaccine.html</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>7</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.nytimes.com/2023/02/01/health/covid-vaccines-covax-gavi-prepayments.html</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>8</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.devex.com/news/j-j-delays-could-leave-south-africa-paying-for-covid-19-vaccine-doses-104154</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The company has not stated how public funding
affects price and has also refused to disclose the vaccine&rsquo;s cost and eventual &ldquo;commercial&rdquo; price, which will likely
vary from country to country. While the company has stated it will distribute a vaccine on a &ldquo;non-profit&rdquo; basis, the commitment
is limited to &ldquo;emergency pandemic use.&rdquo;<SUP>9</SUP>
JNJ committed to an external audit of its non-profit pricing while testifying to Congress in July 2020, but JNJ has not yet fulfilled
that commitment.<SUP>10</SUP> <I>The New York Times</I>
has reported that federal officials estimate the production of the drug substance itself costs only 30<FONT STYLE="background-color: white">&cent;,
with the rest of the $10 emergency price the company has been charging the US government attributed to &ldquo;fill and finish.&rdquo;</FONT><SUP>11</SUP>
<FONT STYLE="background-color: white">JNJ has reportedly sold its shots for between $5 and $10.</FONT><SUP>12</SUP>
<FONT STYLE="background-color: white">At $10 per dose, JNJ&rsquo;s price is double to triple the reported price of another nonprofit vaccine
produced by AstraZeneca that was publicly funded.</FONT><SUP>13</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If and when JNJ does eventually increase the price
of its COVID-19 vaccine &ldquo;post-emergency,&rdquo; which WHO has said may end this year,<SUP>14</SUP>
both the company and its investors could face significant reputational risks for charging a high price for a vaccine for which research,
development and manufacturing has been publicly funded.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
failure of JNJ to share its US government-funded technology could also become a reputational risk. For example, while several governments
including the US shared COVID-19 technologies with the WHO&rsquo;s COVID-19 Technology Access Pool (C-TAP), including vaccine technologies,
JNJ has resisted calls to do the same.</FONT><SUP>15</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"><B>2.</B></TD><TD STYLE="text-align: justify"><B>JNJ faces increased regulatory risks during and after the COVID-19 pandemic due to its failure to be
transparent about the role of public funding in vaccine pricing and access. </B></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">JNJ&rsquo;s lack of pricing transparency and accounting
for public funding for its product risks potential increased regulation and oversight from governments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In recent years, US policymakers have increased
their scrutiny of the role public funding plays in medicine pricing throughout the development pipeline.<SUP>16</SUP>
Public funding is already a factor in the government&rsquo;s price negotiation process under the recently passed Inflation Reduction Act.<SUP>17</SUP>
International stakeholders are also seeking more information about the role of public funding and considering measures to improve access
to current and future pandemic tools. The &ldquo;zero draft&rdquo; of the WHO&rsquo;s &ldquo;Convention, Agreement or Other International
Instrument on Pandemic Prevention, Preparedness and Response&rdquo; also proposes greater transparency of public funding of pandemic response
products, measures to promote access to the results of publicly funded research, and other measures to improve access to pandemic products,
including references to more flexible IP rules.<SUP>18</SUP>
The World Trade Organization has already adopted changes to IP rules for vaccines during the pandemic in an attempt to better balance
IP with access,<SUP>19</SUP> despite strong pharmaceutical
company opposition.<SUP>20</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>9</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.bloomberg.com/news/videos/2021-07-21/j-j-cfo-not-for-profit-vaccine-price-likely-to-end-in-2021-video</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>10</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.congress.gov/116/meeting/house/110926/witnesses/HHRG-116-IF02-Wstate-DouoguihM-20200721.pdf</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>11</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.nytimes.com/2021/03/26/us/biden-coronavirus-vaccine.html</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>12</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.biopharmadive.com/news/johnson-johnson-vaccine-not-for-profit-price/608477/</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">;
https://www.nytimes.com/2021/03/26/us/biden-coronavirus-vaccine.html</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>13</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.pharmaceutical-technology.com/features/covid-19-vaccine-pricing-varies-country-company/</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>14</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing---17-march-2023</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>15</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.warren.senate.gov/oversight/letters/warren-colleagues-call-on-pfizer-moderna-and-johnson-and-johnson-to-expand-access-to-covid-19-vaccines-across-the-globe</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>16</SUP> https://oversight.house.gov/sites/democrats.oversight.house.gov/files/DRUG%20PRICING%20REPORT%20WITH%20APPENDIX%20v3.pdf;
https://aspe.hhs.gov/sites/default/files/private/aspe-files/263451/2020-drug-pricing-report-congress-final.pdf</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>17</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.congress.gov/bill/117th-congress/house-bill/5376/text</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>18</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.keionline.org/wp-content/uploads/WHO-zero-draft-pandemic-treaty-1Feb2023.pdf</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>19</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.wto.org/english/news_e/news22_e/trip_08jul22_e.htm</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>20</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.ifpma.org/resource-centre/pharmaceutical-industry-expresses-deep-disappointment-with-decision-on-waiving-intellectual-property-rights-adopted-at-the-world-trade-organization-ministerial-conference/</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 8pt; margin-bottom: 6pt; border-bottom: Black 2px solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 8pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 8pt Times New Roman, Times, Serif"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If corporations do not voluntarily cooperate with
governments to make their lifesaving products sustainable, equitable, and timely in access, government regulation may be more likely and
more costly. For example, in response to public outcry over the high prices of medicines, the US passed the Inflation Reduction Act enabling
price negotiations for certain medicines under Medicare. Moody&rsquo;s warns that the $100 billion in savings the US government will generate
over 10 years by negotiating prices will be &ldquo;generally borne by the industry.&rdquo;<SUP>21</SUP>
By acting proactively, JNJ can be a leader in modeling transparency and may prevent a situation in which governments regulate and oversee
the company in a manner that affords the company less independence and control and threatens shareholder interests.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><U>III. CONCLUSION</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">JNJ has not explained whether and how receipt
of federal funding is accounted for in its access strategy. Receipt of such funds should be accompanied by transparency, so that investors
can gauge the material risks of receiving this public money while failing to ensure broader public vaccine access. The company has continued
to decline to be transparent on this issue following several years of engagement with investors, in contrast to Pfizer and Moderna, where
investors withdrew similar pricing transparency proposals after the companies agreed to disclose more information about how government
funding factored into pricing and access decisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We urge shareholders to vote <B>&ldquo;For&rdquo;</B>
Item 6.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For more information, please contact Jennifer
Reid at jennifer.reid@oxfam.org.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U></P>







<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><SUP>21</SUP>
<FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">https://www.fiercepharma.com/pharma/us-drug-pricing-reform-here-effects-wont-be-felt-some-time-analysts</FONT></P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2px solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>oxfamlogo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 oxfamlogo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!F17AI9@  34T *@    @ ! $:  4
M   !    /@$;  4    !    1@$H  ,    !  (   $Q  (    0    3@
M      !@     0   &     !<&%I;G0N;F5T(#0N,"XU /_; $,  @$! @$!
M @(" @(" @(#!0,# P,#!@0$ P4'!@<'!P8'!P@)"PD(" H(!P<*#0H*"PP,
M# P'"0X/#0P."PP,#/_; $,! @(" P,#!@,#!@P(!P@,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( 'H
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MN;K"P\3%QL?(R<K2T]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$
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M9TU+,JRMS*T?3J_GLOGT9]!PSE\H)XJHM]%Z=7_D%%%%?JA]<%%%% !1110
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MR1KR4U[S6E^W7]#\[_B+\0X?A+_P4)USQ1<6TMY!H/C*>]D@B8*\H2=B5!/
M)]Z^OOAW_P %?O#GQ$^(&A^'X?!NN6TVN7\%A',]U$5B:614#$#G W9XKY/U
MSP;IWQ$_X*6:AH.KV_VK2]7\;S6MU#O*>9&T[ C*D$?4'-??WA?_ ()Q_!_P
M;XFT_6-.\+-;ZAI=S'=VTG]H7+>7+&P96P7(." <'BM.&*.<3JUY9?4C&'M'
MS*6[UZ>Z^GFB\IIXV4ZCPTDH\SO?_AGT/FG_ (+5_$O[3XH\&^$8Y/ELK>75
MKE0?XG/EQY^@23_OJOG/XL?"_4OV2?B%\/\ 5%:1;JXTG3O$L9/\$V[>Z?\
M 67'XU>_;V^);?$_]L'Q=?Q8N+?3KT:;;+C<K); 1GCN"ZN?QK#_ &B?VG/%
MG[2\NCS>*K?34?0XG@M7M+(V^$?;E6Y.0-HQZ9/K7S.?9A0Q&.Q6(DWS\R4+
M;6B[/TT2:/*S#$TZM>M4?Q77+\M/R/U _:X\06_BS]B'QGJEHV^UU+PV]U"W
MJCQAE_0BOR#LM#OI=#N-6MXY?LNGSQ12SI_RPD<,T?TSY;8/J*_0SX4?$O\
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0Z4Z\<1+XHZ(****],ZC_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
